Holen Sie sich die Stockscreener-App
38.00
8.57%
3.00
Handel nachbörslich:
38.00
Schlusskurs vom Vortag:
$35.00
Offen:
$35.7
24-Stunden-Volumen:
530.66K
Relative Volume:
0.71
Marktkapitalisierung:
$1.71B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.20M
KGV:
-24.28
EPS:
-1.5653
Netto-Cashflow:
$-43.65M
1W Leistung:
+5.41%
1M Leistung:
+4.20%
6M Leistung:
+203.27%
1J Leistung:
+321.29%
1-Tages-Spanne:
$34.71
$38.86
1-Wochen-Bereich:
$34.06
$39.21
52-Wochen-Spanne:
$4.8069
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
38.00 | 1.57B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-12-04 | Eingeleitet | Goldman | Sell |
| 2025-11-04 | Eingeleitet | TD Cowen | Buy |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-08-15 | Fortgesetzt | Jefferies | Buy |
| 2025-08-05 | Eingeleitet | Mizuho | Outperform |
| 2025-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences execs join Feb–Mar health investor events - Stock Titan
MBX Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Profit Recap: Is MBX Biosciences Inc being accumulated by smart moneyWeekly Market Report & Community Driven Trade Alerts - baoquankhu1.vn
MBX Biosciences raises $87.1 million through at-the-market stock offering - Investing.com UK
MBX Biosciences raises $87.1 million through at-the-market stock offering By Investing.com - Investing.com South Africa
MBX Biosciences Raises $87 Million in ATM Offering - TipRanks
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
MBX Biosciences (NASDAQ:MBX) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in MBX Biosciences, Inc. $MBX - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After New Barclays Overweight Coverage - Sahm
How Investors Are Reacting To MBX Biosciences (MBX) Adding Veteran CFO Laurie Stelzer To Its Board - Sahm
MBX Biosciences, Inc. (MBX) Stock Analysis: A Biotech Bet With 65.85% Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. (NASDAQ:MBX) Short Interest Update - MarketBeat
MBX Biosciences (NASDAQ:MBX) Now Covered by Analysts at Barclays - MarketBeat
Barclays Initiates Coverage on MBX Biosciences With Overweight Rating - marketscreener.com
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% - MSN
Risk Off: Is MBX Biosciences Inc part of any ETF2025 Biggest Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MBX Biosciences, Inc. (MBX) Stock Analysis: Exploring a Potential 42.85% Upside in Biotech Innovation - DirectorsTalk Interviews
Assessing MBX Biosciences (MBX) Valuation After A 261% One Year Total Shareholder Return - Yahoo Finance
MBX Biosciences appoints Laurie Stelzer to board of directors By Investing.com - Investing.com Nigeria
MBX Biosciences, Inc. Announces Board and Committee Changes - marketscreener.com
MBX Biosciences appoints Laurie Stelzer to board of directors - Investing.com
MBX Biosciences Appoints Laurie Stelzer to Board, Audit Chair - TipRanks
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair - The Manila Times
Forecast Cut: Should I buy MBX Biosciences Inc stock nowEarnings Overview Report & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
MBX Biosciences (NASDAQ:MBX) Shares Down 6.8%Here's What Happened - MarketBeat
Assessing MBX Biosciences (MBX) Valuation After Guggenheim’s Supportive Obesity Drug Updates - Sahm
Is MBX Biosciences’ (MBX) Once‑Monthly Obesity Strategy Quietly Redefining Its Competitive Moat? - Sahm
Will MBX Biosciences Inc. stock benefit from upcoming earnings reportsWeekly Investment Report & Long Hold Capital Preservation Tips - bollywoodhelpline.com
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Teladoc (TDOC) and Pfizer (PFE) - The Globe and Mail
Guggenheim raises MBX Biosciences stock price target on obesity drug potential - Investing.com Nigeria
MBX Biosciences Surges Amid Strategic Partnership Developments - timothysykes.com
Breakout Watch: What makes MBX Biosciences Inc stock attractive to growth fundsEarnings Summary Report & Real-Time Buy Zone Alerts - Bộ Nội Vụ
Stifel reiterates Buy rating on MBX Biosciences stock, citing obesity drug pipeline - Investing.com Canada
Stifel reiterates Buy rating on MBX Biosciences stock, citing obesity drug pipeline By Investing.com - Investing.com Nigeria
MBX Biosciences (NASDAQ:MBX) Trading 7.6% HigherTime to Buy? - MarketBeat
MBX Biosciences Sees Shares Surge amid Strategic Partnerships - timothysykes.com
MBX Biosciences Highlights 2026 Outlook and Pipeline Progress - TipRanks
Portfolio Shifts: Is MBX Biosciences Inc stock influenced by commodity pricesJuly 2025 Earnings & Fast Moving Trade Plans - baoquankhu1.vn
Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026 - TradingView — Track All Markets
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Drug maker maps out once-monthly obesity shots and hormone disorder trial - Stock Titan
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):